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Background: Oxidative stress plays an important role in diabetes-induced vascular inflammation and pathogenesis.
Nuclear factor E2-related factor-2 (Nrf2) is a transcription factor orchestrating antioxidant and cyto-protective
responses to oxidative stress. In the present study, we tested whether sulforaphane (SFN) can protect the aorta
from diabetes and, if so, whether the aortic protection is associated with up-regulation of Nrf2 and its down-stream
antioxidants.
Methods: Type 1 diabetes was induced in FVB mice by multiple low-dose streptozotocin. Diabetic and
age-matched control mice were treated with or without SFN at 0.5 mg/kg daily in five days of each week for
three months. At the end of 3 months treatment of SFN one set of mice were sacrificed to perform the
experimental measurements. The second set of both diabetic and control mice were aged for additional 3 months
without further SFN treatment and then sacrificed to perform the experimental measurements. Aortas from these
mice were assessed for fibrosis, inflammation, oxidative damage, and Nrf2 expression and transcription by
immunohistochemical staining and real-time PCR method, respectively.
Results: Diabetes induced significant increases in oxidative stress and inflammation in the aorta at both 3 and
6 months, and fibrotic response at 6 months. SFN completely prevented these diabetic pathogenic changes and
also significantly up-regulated the expression of Nrf2 and its down-stream antioxidants.
Conclusions: These results suggest that diabetes-induced aortic fibrosis, inflammation, and oxidative damage can
be prevented by SFN. The aortic protection from diabetes by SFN was associated with the up-regulation of Nrf2
and its downstream antioxidants.
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Systemic complications are the major cause of morbidity
and mortality in patients with either Type 1 or Type 2
diabetes. These complications are divided into micro-
vascular and macrovascular disorders [1,2]. The latter
includes coronary artery disease, atherosclerosis and per-
ipheral vascular disease. Although glucose control, blood* Correspondence: sugf@yahoo.com; L0cai001@louisville.edu
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reproduction in any medium, provided the orpressure control, lipid lowering, and the blockade of the
renin-angiotensin system were used for the treatment of
diabetic patients, the development and progression of
vascular complications in the patients with diabetes
remains unpreventable [1]. Therefore, an effective ap-
proach to prevent or delay the development and pro-
gression of these lethal complications for diabetic
patients are urgently needed.
Increasing evidence indicates that increased production
of reactive oxygen or nitrogen species (ROS or RNS)
and/or impaired endogenously protective mechanism isd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Figure 1 Outline of experimental procedures. Day 0 means that
hyperglycemia was defined at 7 days after multiple low doses of STZ
(MLD-STZ) treatment. SFN: Sulforaphane which was given
subcutaneously at 0.5 mg/kg daily in five days of each week for
3 months. Some of these mice were sacrificed immediately at the
end of the 3-month SFN treatment. The rest mice were sacrificed at
3 months after the 3-month SFN treatment. DM: diabetes.
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progression of vascular complications in diabetic
patients, although several other mechanisms were also
proposed [3-5]. Exogenous supplementation of a single
or few antioxidants in clinics often fails to efficiently pre-
vent or treat various complications for diabetic patients;
therefore up-regulation of endogenous, multiple antioxi-
dants may be a better approach for the prevention of dia-
betic cardiovascular complications [6].
The transcriptional factor NFE2-related factor 2
(Nrf2) as one member of the cap’n’collar family is a
master regulator of cellular detoxification responses
and redox status [7]. Under physiological conditions
Nrf2 locates in the cytoplasm and binds to its inhibi-
tor kelch-like ECH-associated protein 1 (KEAP1) [8].
KEAP1 could mediate a rapid ubiquitination and sub-
sequent degradation of Nrf2 by the proteasome [8].
Upon exposure of cells to oxidative stress or electrophilic
compounds, Nrf2 is free from KEAP1 and translocates
into the nucleus to bind to antioxidant-responsive
elements (ARE) in the genes encoding antioxidant
enzymes such as NADPH quinoneoxidoreductase
(NQO1), heme oxygenase-1 (HO-1), glutathione S-
transferase, superoxide dismutase (SOD), catalase, and
γ-glutamylcysteine synthetase, increasing their expres-
sion to play a role in the detoxification, antioxidant,
and anti-inflammatory [7-9]. Nrf2 is appreciated now
for its potential prevention of or therapy for diabetic
complications [10,11].
Sulforaphane (SFN) is an organosulfur compound
that exhibits anticancer and anti-diabetic properties in
experimental models, and obtained from cruciferous
vegetables such as broccoli, brussels sprouts or cab-
bages [12]. Therefore, increased consumption of crucif-
erous vegetables has been associated with a decreased
risk of several degenerative and chronic diseases, in-
cluding cardiovascular disease. SFN has garnered par-
ticular interests as an indirect antioxidant due to its
extraordinary ability to induce expression of endogen-
ous, multiple enzymes via the up-regulation of Nrf2
function [12].
Therefore the present study aimed to investigate
whether chronic use of SFN can prevent the develop-
ment of diabetes-induced aortic pathogenesis. To the
end, we have used a type 1 diabetic mouse model
induced with multiple low-dose streptozotocin (MLD-
STZ). Diabetic and age-matched control mice were trea-
ted with SFN for 3 months. At the end of 3 months
treatment of SFN one set of mice were sacrificed to per-
form the experimental measurements. The second set of
both diabetic and control mice were aged for additional
3 months without further SFN treatment and then sacri-
ficed to perform the experimental measurements, as illu-
strated in Figure 1.Experimental methods
Animals
FVB male mice, 8–10 weeks of age, were purchased
from the Jackson Laboratory (Bar Harbor, Maine) and
housed in the University of Louisville Research
Resources Center at 22°C with a 12 h light/dark cycle
with free access to standard rodent chow and tap water.
All experimental procedures for these animals were
approved by the Institutional Animal Care and Use
Committee of the University of Louisville, which is com-
pliant with the Guide for the Care and Use of Labora-
tory Animals published by the US National Institutes of
Health (NIH Publication No. 85–23, revised 1996).
For type 1 diabetic mouse model, mice were injected
intraperitoneally with MLD-STZ (Sigma-Aldich, St.
Louis, MO), dissolved in 0.1 M sodium citrate buffer
(pH4.5), at 50 mg/kg body-weight daily for 5 days
while age-matched control mice were received multiple
injections of the same sodium citrate buffer. Five days
after the last injection, mice with hyperglycemia (blood
glucose levels ≥ 250 mg/dl) were considered as diabetic
as before [13]. SFN (Sigma-Aldich) was given subcuta-
neously at 0.5 mg/kg daily in five days of each week
for 3 months. At the end of 3-month SFN treatment
one set of mice were sacrificed to perform the experi-
mental measurements. The second set of both diabetic
and control mice were aged for additional 3 months
without further SFN treatment and then sacrificed to
perform the experimental measurements, as illustrated
in Figure 1. Dose of SFN was selected based on pub-
lished information [14]. Mice were randomly allocated
into four groups (n = 6 at least per group): Control,
SFN, diabetes (DM) and DM plus SFN (DM/SFN), as
outlined in Figure 1. Since SFN was dissolved in di-
methyl sulfoxide (DMSO) and diluted in PBS, mice
serving as vehicle controls were given the same volume
of PBS (1% DMSO).
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After anesthesia, thorax was opened and descending
thoracic aortas were isolated carefully and cleaned of
surrounding fat and connective tissue. Aortas tissues
were fixed in 10% buffered formalin and then cut into
ring segments (2 – 3 mm in length) for being dehy-
drated in graded alcohol series, cleared with xylene, em-
bedded in paraffin, and sectioned at 5 μm thickness for
pathological and immunohistochemical staining.
Paraffin sections (5 μm thickness) from aortic tissues
were dewaxed and incubated with 1X Target Retrieval
Solution (Dako, Carpinteria, CA) in a microwave oven
for 15 min at 98°C for antigen retrieval, with 3% hydro-
gen peroxide for 15 min at room temperature, and then
with 5% animal serum for 30 min, respectively. These
sections were incubated with primary antibodies against
connective tissue growth factor (CTGF) and transform-
ing growth factor (TGF)-β1 at 1:100 dilution (Santa Cruz
Biotechnology, Santa Cruz, CA), 3-nitrotyrosine (3-NT)
at 1:400 dilution (Millipore, Billerica, CA), 4-hydroxy-2-
nonenal (4-HNE) at 1:400 dilution (Alpha Diagnostic
International, San Antonio, TX), plasminogen activator
inhibitor-1 (PAI-1) at 1:100 dilution (BD Bioscience, San
Jose, CA), TNF-α (Abcam, Cambridge, MA)at 1:100 dilu-
tion, Nrf2at 1:100 dilution, and Cu-Zn superoxide
dismutase-1 (SOD-1) at 1:400 dilution (both from Santa
Cruz Biotechnology) overnight at 4°C. After sections
were washed with PBS, they were incubated with horse-
radish peroxidase conjugated secondary antibodies
(1:300 – 400 dilutions with PBS) for 2 h in room
temperature. For the development of color, sections were
treated with peroxidase substrate DAB kit (Vector La-
boratories, Inc. Burlingame, CA) and counterstained with
hematoxylin.
Sirius-red staining for collagen
Aortic fibrosis was reflected by Sirius-red staining for
collagen, as described in our previous study [15].
Briefly, 5 μm tissue sections were used for Sirius-red
staining with 0.1% Sirius-red F3BA and 0.25% Fast
Green FCF. Sections stained for Sirius-red then were
assessed for the proportion of collagen using a Nikon
Eclipse E600 microscopy system
Real-time qPCR
Collected aortas were snap frozen in liquid nitrogen and
kept at - 80°C. Total RNA was extracted using the TRI-
zol Reagent (Invitrogen, USA). RNA concentrations and
purities were quantified using a Nanodrop ND-1000
spectrophotometer. First-strand complimentary DNA
(cDNA) was synthesized from total RNA according to
manufacturer’s protocol from the RNA PCR kit (Pro-
mega, Madison, WI). Reverse transcription was per-
formed using 0.5 μg of total RNA in 12.5 μl of thesolution containing 4 μl 25 mM MgCl2, 4 μl AMV re-
verse transcriptase 5 X buffer, 2 μl dNTP, 0.5 μl RNase
inhibitor, 1 μl of AMV reverse transcriptase, and 1 μl of
oligo dT primer, which were added with nuclease-free
water to make a final volume of 20 μl. Reaction system
was run at 42°C for 50 min and 95°C for 5 min. Primers
of NQO1, HO-1, SOD-1, and β-actin were purchased
from Applied Biosystems (Carlsbad, CA). Real-time
quantitative PCR (qPCR) was carried out in a 20 μl reac-
tion buffer that included 10 μl of TaqMan Universal
PCR Master Mix, 1 μl of primer, 9 μl of cDNA with the
ABI 7300 Real-Time PCR system. The fluorescence in-
tensity of each sample was measured at each
temperature change to monitor amplification of the tar-
get gene. The comparative cycle time (CT) was used to
determine fold differences between samples.
Statistical analysis
Data were collected from several animals and presented
as means ± SD (n = 6). We used Image Pro Plus 6.0
software and a IOD (integrated optical density) divided
area method to identify the positive staining area of
interest. Comparisons were performed by one-way
ANOVA for the different groups, followed by post hoc
pairwise repetitive comparisons using Tukey’s test with
Origin 7.5 Lab data analysis and graphing software.
Statistical significance was considered at P <0.05.
Results
Preventive effect of SFN on diabetes-induced aortic
fibrosis
MLD-STZ-induced diabetic and age-matched control
mice were treated with SFN for 3 months. At the end of
3 months treatment of SFN one set of mice were sacri-
ficed to perform the experimental measurements. The
second set of both diabetic and control mice were kept
for additional 3 months without further SFN treatment
and then sacrificed to perform the experimental mea-
surements, as illustrated in Figure 1. Aortas were exam-
ined pathologically with H&E staining (Figure 2A),
which showed the increase in tunic media thickness
slightly at 3 months and significantly at 6 months of dia-
betes. Similarly Sirius-red staining revealed an increased
collagen accumulation in aortic tunica media of diabetic
mice at 6 months (Figure 2B). Both pathological altera-
tions were completely prevented by SFN treatment,
which was observed not only at the end of the 3-month
SFN treatment, but also 3 months after the 3-month
SFN treatment.
To further examine the preventive effect of SFN on
diabetes-induced aortic fibrosis, immunohistochemical
staining showed the increased expression of two import-
ant pro-fibrotic mediators, CTGF and TGF-β1 (Figure 3A,
B), in aortic tunica media of DM mice, particularly at the
DMControl

































































Figure 2 Preventive effect of SFN on diabetes-induced aortic pathological changes. The pathogenic changes of aortas were examined by
H&E staining (A), and Sirius-red staining for collagen accumulation (B), followed with semi-quantitative analysis. Data were presented as


























































Figure 3 Preventive effect of SFN on diabetes-induced aortic fibrosis. Aortic fibrosis was examined by immunohistochemical staining for the
expression of CTGF (A) and TGF-β1 (B), followed with semi-quantitative analysis. Data were presented as means ± SD (n = 6). *, p < 0.05
vs. control; #, p < 0.05 vs. DM. Bar = 50 μM.
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prevent the fibrotic response in the aortas induced by dia-
betes (i.e.: DM/SFN group).
Preventive effect of SFN on diabetes-induced aortic
inflammation and oxidative damage
Since both inflammation and oxidative damage are major
causative factors for the fibrotic response, the expression
of TNF-α (Figure 4A) and PAI-1 (Figure 4B) as indices of
inflammation was examined with immunohistochemical
staining. Diabetes was found to induce a progressive
increase in aortic inflammation, an effect that was
completely prevented by 3-month treatment with SFN.
Oxidative damage was detected by examining the ac-
cumulation of 4-HNE and 3-NT as indices of lipid per-
oxidation and protein nitration, respectively. Figure 5
shows that diabetes significantly increased aortic accu-
mulation of 4-HNE and 3-NT, both which were found
to be more significant at 3 months than that at 6 months.
However, treatment with SFN for 3 months completely
prevented the oxidative damage at both time-points.
SFN up-regulated Nrf2 expression and transcription
Above results showed that SFN can protect diabetic in-
duction of aortic oxidative stress and damage, inflamma-
tion, and remodeling. Since SFN is an Nrf2 activator,
whether the SFN prevention of diabetes-induced these

















Figure 4 Preventive effect of SFN on diabetes-induced aortic inflamm
staining for the expressions of TNF-α (A) and PAI-1 (B), followed by semi-q
*, p < 0.05 vs. control; #, p < 0.05 vs. DM. Bar = 50 μM.Nrf2 was examined first by measuring Nrf2 expression
with immunofluorescent staining (Figure 6). It was
shown that Nrf2expression significantly increased in
the aorta of SFN-treated control mice both at
3 months (i.e.: at the end of 3-month SFN treatment)
and 6 months (3 months after the end of 3-month
SFN treatment) of diabetes. Diabetes also significantly
increased aortic Nrf2 expression at 3 months, but sig-
nificantly decreased aortic Nrf2 expression at 6 months
of diabetes. There was significantly synergistic increase
in the aortic Nrf2 expression in DM/SFN group at 3-
month time-point compared to DM group or SFN
group.
Immunofluorescent staining also showed that SFN can
increase the nuclear accumulation of Nrf2 in the control
or diabetic aortas (Figure 6), suggesting the activation of
Nrf2 transcriptional function. Therefore we further
explored Nrf2 function by examining the expression of
its downstream anti-oxidative genes, NQO1 (Figure 7A),
HO-1 (Figure 7B), and SOD-1 (Figure 7C). Expression of
these genes at mRNA level was significantly increased in
the aorta of SFN-treated control mice at both 3 months
and 6 months; Diabetes significantly increased at
3 months, but significantly decreased at 6 months, aortic
mRNA expression of these genes. However, aortic
mRNA expression of these genes was significantly higher
in DM/SFN mice than DM mice at both 3 months and











































ation. Aortic inflammation was examined by immunohistochemical



























































Figure 5 Preventive effect of SFN on diabetes-induced aortic oxidative damage. The oxidative damage was examined by
immunohistochemical staining for the accumulation of 4-HNE (A) and 3-NT (B), followed with semi-quantitative analysis. Data were presented as
means ± SD (n = 6).*, p < 0.05 vs. control; #, p < 0.05 vs. DM. Bar = 50 μM.
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SFN-treatment significantly increased the aortic SOD-
1 expression in the control groups at both 3 months
and 6 months; (2) Diabetes significantly increased at
3 months, and significantly decreased at 6 months,
the aortic expression of SOD-1 protein; (3) Aortic ex-
pression of SOD-1 protein was significantly higher inControl DM SFN
3M
6M
Figure 6 Effects of SFN on aortic expression of Nrf2. Aortic expression
expression of Nrf2 in aortic tunica media with semi-quantitative analysis (St
control staining intensity was different between two time-points). Data we
vs. DM. Bar = 50 μM.DM/SFN mice than DM mice at both 3 months and
6 months of diabetes (Figure 7D).
Discussion
The present study provided the first experimental evi-
dence to show the significant protection of the aorta by
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Figure 7 Effects of SFN on aortic expression of Nrf2 downstream genes. Aortic expression of Nrf2 down-stream genes NQO1 (A), HO-1 (B),
and SOD-1 (C) at mRNA levels was measured by real-time PCR. Immunohistochemical staining was used to measure the expression of SOD-1 at
protein levels in aortic tunica media (D) with semi-quantitative analysis (Staining for 3 month & 6 month sections were not performed at same
time so that control staining intensity was different between two time-points). Data were presented as means ± SD (n = 6).*, p < 0.05 vs. control;
#, p < 0.05 vs. DM. Bar = 50 μM.
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ciated with the up-regulation of aortic Nrf2 expression
and transcription. Most importantly, we demonstrated
for the first time that SFN afford aortic protection can
be sustained for long-time (3 months) after stopping the
treatment.
Using MLD-STZ-induced type 1 diabetic mouse model
here the diabetic damage to the aorta was successfully
developed, which is reflected by significantly progressive
increases of aortic fibrosis or remodeling from a slight
increase (p > 0.05) at 3 months of diabetes to a signifi-
cant increase (P < 0.05) at 6 months of diabetes
(Figures 2,3). We also demonstrated that aortic expres-
sion of Nrf2 and its downstream genes in DM group
was significantly increased at 3 months, but significantly
decreased at 6 months of diabetes (Figures. 6,7).
It is known that Nrf2 expression and transcription in
cultured cells in vitro and tissues in vivo are increased in
response to oxidative stress [16-18]. There is strong evi-
dence showing that aging is associated with vascular oxi-
dative stress, which has been causally linked to the
development of cardiovascular diseases. Ungvari et al.
[19] found that in the aorta of Fischer 344 × Brown Nor-
way rats, aging results in a progressive increase in super-
oxide and a decrease in Nrf2 mRNA and protein
expression that was associated with decreases in the nu-
clear Nrf2 activity and the expression of Nrf2 down-stream genes NOQ1 and HO-1. They found an inverse
relationship between vascular expression of Nrf2 target
genes and age-related increases in the expression of the
NF-κB target genes ICAM-1 and IL-6. This study sug-
gested that aging is associated with Nrf2 dysfunction in
the vasculature, which likely exacerbates age-related cel-
lular oxidative stress and increases sensitivity of aged
vessels to oxidative stress-induced cellular damage. In
another study, Ungvari et al. also found that high-fat
diet-induced increases in endothelia ROS levels and
endothelial dysfunction were significantly greater in
Nrf2-KO mice than wild-type mice [20]. These results
suggest that adaptive activation of the Nrf2 pathway
confers endothelial protection under obese and/or dia-
betic conditions. In agreement with these findings, we
also found here that Nrf2 expression in the aorta was
significantly up-regulated in the diabetic mice at
3 months along with no significant damage, but signifi-
cantly down-regulated in the diabetic mice at 6 months
along with significant aortic damage.
The most innovative finding of the present study is that
treatment of diabetic mice for the first 3 months provided
an aortic protection from diabetes, which could be
observed not only at the end of the treatment, but also at
3 months after stopping SFN treatment. In terms of the
mechanism by which SFN-induced aortic protection can
be sustained for long time at least for 3 months it remains
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pression and transcription by SFN is mediated by epigen-
etic modification may be a potential mechanism. The
epigenome is comprised of all chromatin modifications in-
cluding post translational histone modification, expression
control via miRNAs and the methylation of cytosine
within DNA. Modifications of these epigenetic marks not
only allow cells and organisms to quickly respond to chan-
ging environmental stimuli but also confer the ability of
the cell to "memorize" these encounters. Methylation of
CpG repeats in the upstream/promoter regions of genes is
an established mechanism of gene silencing in many cell
types. DNA methylation results in the recruitment of his-
tone deacetylases (HDACs) to promoter regions, thereby
repressing expression of genes. For instance in transgenic
adenocarcinoma of the mouse prostate (TRAMP) model,
the suppressed expression of Nrf2 gene in TRAMP
tumors was because the specific CpG sites of Nrf2 gene
promoter region were hypermethylated [21-23]. There-
fore, anything that can inhibit DNA methyltransferases ac-
tivity has potential to demethylate the CpG sites of Nrf2
gene promoter region, leading to repression of Nrf2 gene
[22,23]. SFN was recently reported to have the function to
demethylate certain hypermethylated sites to repress the
target gene expression [24]. Therefore, SFN may repress
Nrf2 expression under diabetic condition, which may be-
come the sustained (memorized) up-regulation of Nrf2
gene and aortic protection from diabetes.
Conclusions
We have investigated whether SFN as one of Nrf2 acti-
vators can protect the aorta from diabetes using a Type
1 diabetes model. We treated diabetic and age-matched
control mice with SFN at 0.5 mg/kg for 3 months,
resulting in a significant prevention of diabetes-induced
progression of aortic pathogenic damage. The aortic pro-
tection by SFN treatment at early stage was still remark-
able, examined at the late stage of the diabetes, i.e.: at
3 months after stopping SFN treatment. The aortic pro-
tection from diabetes was accompanied with a signifi-
cant up-regulation of Nrf2 expression and function.
These results suggest that diabetic damage to the aorta
can be prevented by SFN most likely via up-regulation
of Nrf2 expression and function.
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